查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198769

关节内置换疗法市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Viscosupplementation Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内 (2023-2028)，关节内置换疗法市场预计将以 5.8% 的复合年增长率增长。

COVID-19 大流行的出现影响了关节内置换疗法市场，因为世界各国政府实施的封锁限制导致医院和门诊手术中心的就诊人数减少。. 由于这些限制，医院停止了非紧急手术，影响了患者的生命。 例如，Enrico Ragni 等人在临床药理学和治疗学杂誌上发表的一项研究 Risk 有望启动。 因此，临床医生和整形外科医生不仅应仔细检查骨关节炎患者的症状管理，还应仔细检查 COVID-19 大流行期间骨关节炎治疗可能导致的合併症，这需要进行评估。 由于上述因素，预计所研究的市场将在大流行期间受到影响。 然而，由于程序的重新开放、医院就诊量的增加和对 COVID-19 的放鬆管制，预计在此期间市场将获得潜力。

推动市场增长的某些因素包括越来越多的骨关节炎患者以及越来越多地引入先进和组合产品。 例如，根据美国疾病控制与预防中心2020年4月发表的一篇题为“骨关节炎”的文章，美国约有3250万人患有骨关节炎。 除此之外，62% 的女性患有骨关节炎。 同样，根据国家生物技术信息中心 2021 年 1 月发表的论文《哈里亚纳邦 Ballabgarh 农村地区老年人膝骨关节炎的患病率及其决定因素及其对生活质量的影响》，64.3% 的老年人患有膝骨关节炎和患有膝关节炎的老年人的生活质量明显较差。 此外，肥胖也是骨科疾病的危险因素。 例如，根据国家生物技术信息中心 2021 年发表的题为“Prevalence of Obesity in India and its Neurological Implications”的论文《Prevalence of Obesity in India and its Neurological Implications》。 一项全国性横断面研究的多因素分析”：印度的肥胖患病率为 40.3%，南印度最高，为 46.51%，东印度最高，为 32.96%。因此，骨关节炎患者的负担增加将增加对关节内替代疗法的需求，关节内替代疗法通过增加关节间润滑来减轻关节疼痛，预计将在预测期内持续。据认为，这将增加中期的市场增长。

但是，监管问题和对关节内置换疗法的认识不足可能会限制市场扩张。

关节内置换疗法市场趋势

在预测期内，预计单一注入段将继续保持较高的复合年增长率

单次注射领域对门诊手术有很高的需求，重点是提高医生和患者的便利性并提供当日手术护理，包括预防（手术）和诊断程序，骨关节炎预计在此期间将出现强劲增长以等因素，更多的公司专注于开发单针剂用于治疗。

越来越多的公司专注于开发单剂量注射剂来治疗骨关节炎患者。 例如，2021 年 10 月，Seikagaku 公司在台湾推出了 Hylink，一种用于治疗膝骨关节炎的单次关节内註射关节内替代疗法。 2020 年 9 月，Bioventus 用于治疗骨关节炎 (OA) 相关疼痛的单次注射透明质酸 (HA) DUROLANE 达到了全球两百万次治疗的里程碑，实现了结石。 同样，2021 年 8 月，Flexion Therapeutics, Inc. 将推出 ZILRETTA（曲安奈德缓释单次注射剂）用于治疗肩骨关节炎 (OA) 和肩关节囊粘连 (AC) 患者。 2 景天混悬液的药代动力学（PK）研究）。

因此，上述因素预计将增加单次注射的需求，进而推动预测期内关节内替代疗法市场的增长率。

预计北美将占据较大的市场份额

由于骨关节炎和相关疾病患病率上升、老年人口不断增加、医疗保健基础设施发达以及对非手术程序的需求不断增加等因素，北美将在预测期内成为世界上最大的市场。它是有望主导关节内替代疗法市场。

关节炎、骨关节炎和膝关节疼痛的负担日益加重，是推动该地区关节内置换疗法市场需求的关键因素。 例如，根据 2021 年加拿大统计局的数据，到 2020 年，大约有 590 万加拿大成年人患有关节炎。 关节炎的患病率随着年龄的增长而增加，并且在女性中更高。 此外，根据美国疾病控制与预防中心 (CDC) 于 2021 年 10 月更新的数据，美国约有四分之一 (23.7%) 的成年人，即约 5850 万人，被医生诊断为关节炎。据说有 同样，根据加拿大政府在 2020 年 9 月的数据，大约 374,000 名 16 岁及以上的加拿大人 (1.2%) 被诊断患有类风湿性关节炎。 因此，随着患者关节炎和膝痛病例的增加，关节内替代疗法的需求预计将增加，从而推动预测期内的市场增长率。

此外，随着老年人口的增加，患有各种关节炎问题的人数将会增加，这将增加对非手术程序的需求，这可能会增加市场增长。 例如，根据美国健康排名2021年高级报告中公布的数据，美国65岁及以上的成年人超过5400万，占总人口的16.5%，老年人口总数到 2050 年，65 岁及以上的人口预计将增长到 8570 万，约占总人口的 20%。

此外，越来越多的公司专注于开发关节内替代疗法来治疗骨关节炎和患者的关节痛，这也促进了该地区的整体市场增长。 例如，2021 年 1 月，Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare 将开发疼痛治疗药物，并在加拿大联合推出 NeoVisc+2 mL 和 NeoVisc ONE 4 mL 以改进功能。

因此，预计在预测期内，关节炎和相关疾病负担的增加、老年人口的增加以及产品发布的增加将推动该地区的市场增长。

关节内置换疗法市场的竞争对手分析

全球关节内置换疗法市场竞争激烈，主要参与者采用合作伙伴关係、产品发布、批准和协作等各种商业策略来维持其市场地位。 主要市场参与者包括 Anika Therapeutics, Inc.、Bioventus LLC、Ferring Pharmaceuticals、Fidia Farmaceutici s.p.a.、Sanofi SA、Johnson & Johnson Services, Inc.、Zimmer Biomet、Wellchem Pharmaceuticals Pte Ltd.和 OrthogenRx Inc。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 越来越多的骨关节炎患者
    • 介绍高性能产品和组合产品
  • 市场製约因素
    • 监管问题，意识低下
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 按剂量
    • 单剂量
    • 3 次注射
    • 5 次注射
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Anika Therapeutics, Inc.
    • Bioventus LLC
    • Chugai Pharmaceuticals Co., Ltd.（Roche）
    • Ferring Pharmaceuticals
    • Fidia Farmaceutici s.p.a.
    • Zimmer Biomet
    • OrthogenRx Inc.
    • Sanofi SA
    • Seikagaku Corporation
    • Aptissen
    • Johnson & Johnson Services, Inc.
    • Wellchem Pharmaceuticals Pte Ltd.

第7章 市场机会与今后动向

简介目录
Product Code: 69923

The viscosupplementation market is projected to grow with a CAGR of 5.8% during the forecast period (2023 - 2028).

The emergence of the COVID-19 pandemic had its impact on the viscosupplementation market due to the decline in visits to hospitals and ambulatory surgical centers because of lockdown restrictions imposed by various governments globally. Due to these restrictions, non-emergency procedures were halted in the hospitals, which have impacted the patient's life. For instance, according to a study published in the Clinical Pharmacology and Therapeutics Journal in May 2020 by Enrico Ragni et al., the presence of osteoarthritis-related concomitant disorders is expected to initiate life-threatening risks for osteoarthritis patients in the event of SARS-CoV2 viral infection. This has prompted clinicians and orthopedists to carefully check and evaluate osteoarthritis patients, not just for symptom management but also for comorbidities that may arise as a result of osteoarthritis treatment during the COVID-19 pandemic. As a result of the aforementioned factors, the market under study is projected to be impacted during the pandemic era. However, with the resumed procedures and increased hospital visits, and lessening of COVID-19 restrictions, the market is expected to gain its potential over the period.

Certain factors that are driving the market growth include the rising patient pool suffering from osteoarthritis and the increasing introduction of advanced and combination products. For instance, according to an article published by the Centers for Disease Control and Prevention in April 2020, titled "Osteoarthritis", about 32.5 million people in the United States are suffering from osteoarthritis. In addition to this, 62% of women suffer from osteoarthritis. Similarly, according to an article published by the National Center for Biotechnology Information, in January 2021, titled "Prevalence of knee osteoarthritis, its determinants, and impact on the quality of life in elderly persons in rural Ballabgarh, Haryana", it has been observed that 64.3% of the elder population is suffering from knee osteoarthritis and the elderly patients with knee osteoarthritis have considerably poorer quality-of-life. Furthermore, obesity is another risk factor contributing to orthopedic conditions. For instance, according to an article published by the National Center for Biotechnology Information, in 2021, titled "Prevalence of Obesity in India and its Neurological Implications: A Multifactor Analysis of a Nationwide Cross-Sectional Study,": the prevalence rate of obesity in India is found to be 40.3%. In addition to this, it has been that the highest rate of prevalence is found in South India with 46.51%, and the lowest in East India with 32.96%. Thus, the increasing burden of osteoarthritis in patients is likely to increase the demand for viscosupplementation procedures, which reduces the pain in joints by increasing the lubrication between them, thereby increasing the market growth over the forecast period.

However, the regulatory issues and lack of awareness regarding the viscosupplementation are likely to restrain the market expansion.

Viscosupplementation Market Trends

Single Injection Segment Expects to Register a High CAGR in the Forecast Period

The single injection segment is expected to witness significant growth over the period, owing to the factors such as providing greater physician and patient convenience, high demand for outpatient surgeries that focus on offering same-day surgical care, including preventive (surgical) and diagnostic procedures, and increasing focus of companies to develop single injection for the treatment of osteoarthritis and rising product launches.

The increasing company focuses on developing single injection products and offering treatment to patients with osteoarthritis. For instance, in October 2021, Seikagaku Corporation launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan. In addition, in September 2020, Bioventus reached milestones with 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). Similarly, in August 2021, Flexion Therapeutics, Inc. announced the positive results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release single injectable suspension) for the treatments of patients with shoulder osteoarthritis (OA) and adhesive capsulitis (AC) trial.

Thus, the aforementioned factors are likely to increase the demand for single injection, thereby increasing viscosupplementation market growth over the forecast period.

North America is Expected to Have the Significant Market Share

North America is expected to dominate the global viscosupplementation market over the forecast period, owing to factors such as the rising prevalence of osteoarthritis and related disorders, the rising geriatric population, well-developed healthcare infrastructure, and the increasing demand for non-surgical procedures.

The rising burden of arthritis, osteoarthritis, and knee pain is the key factor driving the demand for the viscosupplementation market in the region. For instance, according to Statistics Canada 2021, approximately 5.9 million adult Canadians had arthritis in 2020. The prevalence of arthritis increases with age and is higher among females. In addition, according to the Centers for Disease Control and Prevention (CDC) updated in October 2021, about 1 in 4 United States adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis. Similarly, according to the Government of Canada in September 2020, approximately 374,000 (1.2%) Canadians aged 16 years and older live with diagnosed rheumatoid arthritis. Thus, the demand for viscosupplementation increases with the increasing cases of arthritis and knee pain in patients, which is expected to increase the market growth over the forecast period.

In addition, with an increase in the geriatric population, there is a rise in the number of people suffering from various arthritis problems which increases the demand for non-surgical procedures thereby increasing the market growth. For instance, according to the data published by America's Health Ranking in 2021 Senior Report, in the United States, there are more than 54 million adults aged 65 and older which accounts for 16.5% of the total population and the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million, accounting approximately 20% of the total population, by 2050.

Furthermore, the rising company's focus on developing viscosupplements for treating osteoarthritis and joint pain in patients is also contributing to the overall growth of the market in the region. For instance, in January 2021, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL, for the treatment of pain and improvement of joint functionality in patients affected by degenerative (age-related changes) or mechanical arthropathy (related to overuse) of the knee, in Canada.

Thus, the rising burden of arthritis and related disorders, the growing geriatric population, and increasing product launches are expected to increase the market growth in this region over the forecast period.

Viscosupplementation Market Competitor Analysis

The global viscosupplementation market is competitive with the presence of major players adopting various business strategies such as partnerships, product launches, approvals, and collaboration to withhold their market position. Some of the key market players are Anika Therapeutics, Inc., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici s.p.a., Sanofi SA, Johnson & Johnson Services, Inc., Zimmer Biomet, Wellchem Pharmaceuticals Pte Ltd., and OrthogenRx Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Patient Pool Suffering from Osteoarthritis
    • 4.2.2 Introduction of Advanced and Combination Products
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Issues and Lack of Awareness
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Dosage
    • 5.1.1 Single Injection
    • 5.1.2 Three Injection
    • 5.1.3 Five Injection
  • 5.2 By End-User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anika Therapeutics, Inc.
    • 6.1.2 Bioventus LLC
    • 6.1.3 Chugai Pharmaceuticals Co., Ltd. (Roche)
    • 6.1.4 Ferring Pharmaceuticals
    • 6.1.5 Fidia Farmaceutici s.p.a.
    • 6.1.6 Zimmer Biomet
    • 6.1.7 OrthogenRx Inc.
    • 6.1.8 Sanofi SA
    • 6.1.9 Seikagaku Corporation
    • 6.1.10 Aptissen
    • 6.1.11 Johnson & Johnson Services, Inc.
    • 6.1.12 Wellchem Pharmaceuticals Pte Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS